Oral administration of the pimelic diphenylamide HDAC inhibitor HDACi 4b is unsuitable for chronic inhibition of HDAC activity in the CNS in vivo.

Oral administration of the pimelic diphenylamide HDAC inhibitor HDACi 4b is unsuitable for chronic inhibition of HDAC activity in the CNS in vivo.

Histone deacetylase (HDAC) inhibitors have received considerable attention as potential therapeutics for a variety of cancers and neurological disorders. Recent publications on a class of pimelic diphenylamide HDAC inhibitors have highlighted their promise in the treatment of the neurodegenerative d...

Full description

Bibliographic Details
Main Authors: Maria Beconi, Omar Aziz, Kim Matthews, Lara Moumné, Catherine O'Connell, Dawn Yates, Steven Clifton, Hannah Pett, Julie Vann, Lynsey Crowley, Alan F Haughan, Donna L Smith, Ben Woodman, Gillian P Bates, Fred Brookfield, Roland W Bürli, George McAllister, Celia Dominguez, Ignacio Munoz-Sanjuan, Vahri Beaumont
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3433414?pdf=render

Internet

http://europepmc.org/articles/PMC3433414?pdf=render

Similar Items